Invuity (NASDAQ:IVTY)‘s stock had its “buy” rating reissued by research analysts at Northland Securities in a research report issued to clients and investors on Wednesday. They presently have a $6.00 target price on the medical instruments supplier’s stock. Northland Securities’ price target would suggest a potential upside of 51.90% from the company’s current price.
The analysts wrote, “We would be remiss in not expressing our disappointment, and are lowering our PT to $6.””
Several other research firms have also weighed in on IVTY. Zacks Investment Research lowered Invuity from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Piper Jaffray Companies reissued a “buy” rating and issued a $12.00 target price on shares of Invuity in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Invuity currently has an average rating of “Buy” and an average price target of $8.50.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlueCrest Capital Management Ltd acquired a new stake in shares of Invuity during the fourth quarter worth about $139,000. Eversept Partners LLC acquired a new stake in shares of Invuity during the fourth quarter worth about $279,000. CAPROCK Group Inc. raised its position in shares of Invuity by 28.6% during the third quarter. CAPROCK Group Inc. now owns 45,000 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 10,000 shares during the period. OxFORD Asset Management LLP acquired a new stake in shares of Invuity during the second quarter worth about $374,000. Finally, Wells Fargo & Company MN raised its position in shares of Invuity by 987.0% during the fourth quarter. Wells Fargo & Company MN now owns 64,198 shares of the medical instruments supplier’s stock worth $398,000 after purchasing an additional 58,292 shares during the period. 67.57% of the stock is currently owned by institutional investors.
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.